VEGFA and colorectal carcinoma: Other available drugs approved as second-line treatment for mCRC, Ziv-aflibercept (Zaltrap; Regeneron Pharmaceuticals, Tarrytown, NY, USA) a fully humanized recombinant fusion protein that blocks VEGF-A with higher binding affinity than Bevacizumad [97] and Ramucirumab (Cyramza; Eli Lilly, Indianapolis, IN, USA) a fully humanized IgG1completely humanized monoclonal antibody (mAb) targeting the extracellular domain of VEGF, both of which have demonstrated efficacy for second-line use against CRC in combination with leucovorin and ironotecan (FOLFIRI) or irinotecan alone.